Provided by Tiger Trade Technology Pte. Ltd.

Agree

80.33
-0.1600-0.20%
Volume:227.29K
Turnover:18.25M
Market Cap:9.64B
PE:45.38
High:80.56
Open:80.19
Low:79.50
Close:80.49
52wk High:82.08
52wk Low:68.98
Shares:120.03M
Float Shares:108.37M
Volume Ratio:0.43
T/O Rate:0.21%
Dividend:3.08
Dividend Rate:3.84%
EPS(TTM):1.77
EPS(LYR):1.77
ROE:3.48%
ROA:2.37%
PB:1.58
PE(LYR):45.38

Loading ...

Chengdu Hosts Nearly 70% of Sichuan's Corporate Headquarters: The Story Behind the Numbers

Deep News
·
Jan 08

HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma

Stock News
·
Jan 08

Top News Today/Canada: Air Transat, Pilots Agree to Deal

Dow Jones
·
Jan 07

Agree Realty Corporation Schedules Earnings Release and Conference Call

Reuters
·
Jan 07

Agree Realty Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Information

THOMSON REUTERS
·
Jan 07

U.K. and France Agree to Set Up Military Hubs Across Ukraine After Ceasefire -- WSJ

Dow Jones
·
Jan 07

Agree Realty Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 07

Day One Completes Acquisition of Mersana Therapeutics

GlobeNewswire
·
Jan 06

RBC Lowers Price Target on Agree Realty to $79 From $80, Keeps Outperform Rating

MT Newswires Live
·
Jan 06

BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program

Stock News
·
Jan 06

Agree Realty Projects 2026 Investment Volume of $1.25 Billion to $1.50 Billion

Reuters
·
Jan 06

Agree Realty Corp - 2026 Investment Guidance $1.25 Bln to $1.50 Bln

THOMSON REUTERS
·
Jan 06

Agree Realty Announces 2025 Investment Activity & 2026 Investment Outlook

THOMSON REUTERS
·
Jan 06

Australia Reopens Steel Export Market to Indonesia

Tempo
·
Jan 06

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

GlobeNewswire
·
Jan 05

SKB BIO-B (06990) Core Product TROP2 ADC Sac-TMT Combined with Immunotherapy Pembrolizumab Receives NMPA Breakthrough Therapy Designation for First-Line Treatment of PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Stock News
·
Jan 05

SKB BIO-B (06990): ITGB6 ADC SKB105 New Drug Clinical Trial Application Approved by NMPA

Stock News
·
Jan 04

Hong Kong Stocks Movement | Hengrui Pharma (01276) Surges Over 5% in Afternoon Session as CLDN18.2 ADC Gastric Cancer Indication Included in Breakthrough Therapy List

Stock News
·
Jan 02

Agree Realty Director John Rakolta Jr. Reports Acquisition of Common Shares

Reuters
·
Dec 30, 2025

Genmab Halts Development of Investigational Cancer Therapy

Deep News
·
Dec 29, 2025